Leap Therapeutics Inc. (NASDAQ: LPTX) kicked off on January 23, 2023, at the price of $0.7427, down -9.26% from the previous trading day. During the day, the shares moved up to $0.75 and dropped to $0.6201 before settling in for the closing price of $0.72. Over the past 52 weeks, LPTX has traded in a range of $0.40-$2.57.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
While this was happening, its average annual earnings per share was recorded 25.40%. With a float of $82.38 million, this company’s outstanding shares have now reached $113.24 million.
Let’s determine the extent of company efficiency that accounts for 36 employees.
Leap Therapeutics Inc. (LPTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Leap Therapeutics Inc. is 9.26%, while institutional ownership is 44.50%.
Leap Therapeutics Inc. (LPTX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/29/2022, the organization reported -$0.15 earnings per share (EPS), lower than consensus estimate (set at -$0.1) by -$0.05. This company achieved a net margin of -2705.80 while generating a return on equity of -52.53. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.49% during the next five years compared to 29.60% growth over the previous five years of trading.
Leap Therapeutics Inc. (NASDAQ: LPTX) Trading Performance Indicators
Take a look at Leap Therapeutics Inc.’s (LPTX) current performance indicators. Last quarter, stock had a quick ratio of 6.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 121.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.39 in one year’s time.
Technical Analysis of Leap Therapeutics Inc. (LPTX)
Looking closely at Leap Therapeutics Inc. (NASDAQ: LPTX), its last 5-days average volume was 2.74 million, which is a jump from its year-to-date volume of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 62.98%. Additionally, its Average True Range was 0.08.
During the past 100 days, Leap Therapeutics Inc.’s (LPTX) raw stochastic average was set at 17.29%, which indicates a significant decrease from 63.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 165.63% in the past 14 days, which was higher than the 101.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5333, while its 200-day Moving Average is $1.0099. However, in the short run, Leap Therapeutics Inc.’s stock first resistance to watch stands at $0.7283. Second resistance stands at $0.8041. The third major resistance level sits at $0.8582. If the price goes on to break the first support level at $0.5984, it is likely to go to the next support level at $0.5443. Now, if the price goes above the second support level, the third support stands at $0.4685.
Leap Therapeutics Inc. (NASDAQ: LPTX) Key Stats
The company with the Market Capitalisation of 48.46 million has total of 99,021K Shares Outstanding. Its annual sales at the moment are 1,500 K in contrast with the sum of -40,590 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -15,094 K.